Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Apyx Medical (NASDAQ: APYX) will release its financial results for the second quarter of fiscal year 2026 after market close on Thursday, August 6, 2026.

Rhea-AI Summary

Apyx Medical (NASDAQ: APYX) will release its financial results for the second quarter of fiscal year 2026 after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. Eastern Time the same day to discuss the results and hold a Q&A session.

Investors can join by phone using access code 53282 at 800-717-1738 (U.S.) or 646-307-1865 (international), or via a live webcast available through the company’s Investor Relations website, where a replay will be archived.

Argus Jul 23 session 1 alert

-2.05% close to close 0.0x rel. volume Open Argus

Details

News Market Reaction – APYX

$164.65M Market Cap

On Jul 23, the day this news came out, APYX closed 2.05% below the previous close.

Data tracked by StockTitan Argus for the Jul 23 session.

Market Context

Two tag-matched earnings-date notices averaged a -2.08% 24-hour move, adding historical context to t...

Analysis

Two tag-matched earnings-date notices averaged a -2.08% 24-hour move, adding historical context to this scheduling announcement. The upcoming results provide the substantive checkpoint, while low short positioning is the sourced risk factor.

Key Figures

Fiscal quarter: Q2 fiscal year 2026 Results release date: August 6, 2026 Conference call time: 4:30 p.m. Eastern Time +1 more

Fiscal quarter

Q2 fiscal year 2026

Financial results scheduled for release

Results release date

August 6, 2026

After markets close

Conference call time

4:30 p.m. Eastern Time

August 6, 2026

Clinical documents

More than 90 clinical documents

Supporting Renuvion and J-Plasma effectiveness

Previous Earnings date Reports

2 past events · Latest: Apr 23

Same Type 2 events

1. Apr 23

   Earnings date

   24h Move

   -0.8%

   First-quarter fiscal 2026 results release and conference call were scheduled for May 7

2. Feb 25

   Earnings date

   24h Move

   -3.4%

   Fourth-quarter fiscal 2025 results release and conference call were scheduled for March 10

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fda-cleared, electrosurgical, oem agreements

3 terms

fda-cleared regulatory

"The AYON Body Contouring System is an FDA-cleared, groundbreaking"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

electrosurgical medical

"closed loop contouring, electrosurgical capabilities and Renuvion"

Electrosurgical describes tools and procedures that use controlled electric current to cut, seal, or stop bleeding in body tissues during medical procedures, similar to using a heated knife or a precise spark instead of a scalpel. For investors, electrosurgical products matter because they drive sales, device adoption, regulatory reviews, and liability risk in the surgical devices market—factors that affect revenue, profit margins, and company valuations.

oem agreements financial

"through OEM agreements with other medical device manufacturers"

OEM agreements are contracts where one company makes products or components that another company sells under its own brand, like a bakery baking cakes that a café sells with the café’s name. For investors, these deals matter because they influence cost structure, product quality, supply reliability and how much control a brand has over manufacturing; strong OEM partnerships can speed growth but can also create dependence on outside suppliers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System^™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, August 6^th.

Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 6^th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 53282. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion^® and the AYON Body Contouring System^™ in the cosmetic surgery market and J-Plasma^® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Apyx Medical (NASDAQ: APYX) report its Q2 2026 financial results?

Apyx Medical will report its Q2 2026 financial results on Thursday, August 6, 2026, after markets close. According to Apyx Medical, the release will be followed by a management conference call and Q&A at 4:30 p.m. Eastern Time the same day.

How can investors join the Apyx Medical (APYX) Q2 2026 earnings conference call?

Investors can join the Apyx Medical Q2 2026 call by dialing 800-717-1738 (U.S.) or 646-307-1865 (international) with access code 53282. According to Apyx Medical, participants should request the “Apyx Medical Corporation Call” when connected.

Will there be a webcast for the Apyx Medical (APYX) Q2 2026 earnings call?

Yes, Apyx Medical will provide a live webcast of its Q2 2026 earnings call via the Apyx Medical Earnings Webcast link and the Investor Relations section of its website. According to Apyx Medical, the webcast will also be archived for future reference.

What time is the Apyx Medical (APYX) Q2 2026 earnings call on August 6, 2026?

The Apyx Medical Q2 2026 earnings call is scheduled for 4:30 p.m. Eastern Time on August 6, 2026. According to Apyx Medical, the call will follow the after-market release of quarterly financial results and include a question-and-answer session.

What does Apyx Medical (APYX) do in the surgical aesthetics market?

Apyx Medical is a surgical aesthetics company focused on its Helium Plasma Platform Technology, including Renuvion and the AYON Body Contouring System. According to Apyx Medical, these systems support cosmetic and surgical procedures with controlled heat, body contouring, and related electrosurgical capabilities.